Last reviewed · How we verify
PFS of SB5
PFS of SB5 is a Biologic drug developed by Samsung Bioepis Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | PFS of SB5 |
|---|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis (PHASE2)
- Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PFS of SB5 CI brief — competitive landscape report
- PFS of SB5 updates RSS · CI watch RSS
- Samsung Bioepis Co., Ltd. portfolio CI
Frequently asked questions about PFS of SB5
What is PFS of SB5?
PFS of SB5 is a Biologic drug developed by Samsung Bioepis Co., Ltd..
Who makes PFS of SB5?
PFS of SB5 is developed by Samsung Bioepis Co., Ltd. (see full Samsung Bioepis Co., Ltd. pipeline at /company/samsung-bioepis-co-ltd).
What development phase is PFS of SB5 in?
PFS of SB5 is in Phase 1.
Related
- Manufacturer: Samsung Bioepis Co., Ltd. — full pipeline
- Compare: PFS of SB5 vs similar drugs
- Pricing: PFS of SB5 cost, discount & access